Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the ...

Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Zepbound is a medicine you can obtain only by prescription, and it's typically used to address obesity and other ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...